15.86
+4.34%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Xeris Biopharma Holdings
From its filings with the US Securities and Exchange Commission
Xeris Biopharma Holdings is based in Chicago, Illinois. Its shares trade on Nasdaq under the ticker XERS. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $291.8m and net income of $554,000. At that date it held total assets of $383.5m and shareholders' equity of $13.7m.
Xeris Biopharma Holdings, Inc. along with its subsidiaries, is referenced herein as the "Company", "Xeris", "Xeris Biopharma", "we" or "our". Throughout this document, unless otherwise noted, references to Gvoke include Gvoke PFS, Gvoke HypoPen, and Gvoke Kit.
We are a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. We offer Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing’s syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis ("PPP"). We are advancing our Phase 3-ready pipeline product, XP-8121, once-weekly subcutaneous ("SC") levothyroxine, which leverages our proprietary technology XeriSol.
We prioritize our development efforts on programs that leverage our commercial capabilities or our proprietary formulation technologies, principally our lead pipeline program, XP-8121. Our company name, Xeris, is derived from the ancient Greek word xērós meaning 'dry' or 'without water/non-aqueous'. Our proprietary, non-aqueous formulations are designed to enable the convenient injection of medicines previously uninjectable or poorly injectable when utilizing aqueous approaches. XeriSol and XeriJect offer the opportunity to create ready-to-use, room-temperature stable, highly concentrated, injectable formulations of both small and large molecules.
Quoted from its 10-K, filed 2 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 21 Jun 2018
- Employees
- 435
- Website
- xerispharma.com ↗
- Head office
- 1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL, 60607
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Ms. Marla PerskyIndependent Chairman of the Board$208,583
- Mr. Kevin McCullochPresident, Chief Operating Officer$2.6m
- Mr. John ShannonChief Executive Officer, Director, since 2017$3.8m
- Mr. Steven PieperChief Financial Officer$1.9m
- Dr. Anh NguyenChief Medical Officer
- Ms. Beth HechtChief Legal Officer, Corporate Secretary, since 2021$2.6m
- Dr. BJ BormannIndependent Director$191,500
- Mr. James BradyIndependent Director
- Ms. Dawn HalkuffIndependent Director$186,083
- Mr. John JohnsonIndependent Director$176,500
- Dr. Garheng KongIndependent Director$181,500
- Dr. Jeffrey ShermanIndependent Director$184,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 40
- Environment
- 44
- Social
- 41
- Governance
- 37
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Xeris Biopharma's XeriSol and XeriJect technologies enable stable injectable formulations for peptides and proteins.
- The Glucagon Rescue Pen provides a simple two-step subcutaneous delivery for severe hypoglycemia treatment.
- Xeris employs 435 full-time employees in the US Health Care sector with a focus on innovative pharmaceuticals.
Weaknesses
- Xeris Biopharma's lead product Glucagon Rescue Pen is still in development for severe hypoglycemia treatment.
- The company has only one major product candidate currently in clinical trials.
- Xeris operates with a limited number of employees compared to larger pharmaceutical firms.
Opportunities
- Xeris Biopharma can expand its product pipeline for post-bariatric hypoglycemia treatments.
- The growing diabetes market offers significant opportunities for Glucagon Rescue Pen adoption.
- Xeris can leverage its non-aqueous formulation technology for new drug delivery applications.
Threats
- Xeris Biopharma faces competition from established pharmaceutical companies in the Health Care sector.
- Regulatory approval delays could impact the launch of Glucagon Rescue Pen.
- The company's reliance on a single product candidate poses a significant business risk.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.